A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine

Journal of Physiology Paris

Volumn 93, Issue 6, 1999, Pages 505-512

  Sikiric, Predrag ^a   Marovic, Anton ^a   Matoz, Wendy ^a   Anic, Tomislav ^a   Buljat, Gojko ^a   Mikus, Darko ^a   Stancic Rokotov, Dinko ^a   Šeparovic, Jadranka ^a   Seiwerth, Sven ^a   Grabarevic, Zeljko ^a   Rucman, Rudolf ^a   Petek, Marijan ^a   Ziger, Tomislav ^a   Sebecic, Božidar ^a   Zoricic, Ivan ^a   Turkovic, Branko ^a   Aralica, Gorana ^a   Perovic, Darko ^a   Duplancic, Božidar ^a   Lovric Bencic, Martina ^a   Rotkvic, Ivo ^a   Mise, Stjepan ^a   Jagic, Vjekoslav ^a   Hahn, Vladimir ^a   more..

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antiparkinsonian activity; Brain gut axis; Hypothermy reduction; Mice; MPTP; New gastric juice peptide BPC; Parkinson's disease; Parkinsongenic agents; Reserpine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; RESERPINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CATALEPSY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; STOMACH LESION; TREMOR;

EID: 0033387962     PISSN: 09284257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4257(99)00119-9     Document Type: Conference Paper

References (55)

1. Adams J.D., Odunze I.N. Commentary. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem. Pharmacol. 41:1991;1099-1105.
2. Adams J.D., Kalivas P.W., Miller C.W. The acute histopathology of MPTP in the mouse CNS. Brain Res. Bull. 23:1989;1-17.
3. Ahmed A., Marshall P.B. Relationship between anti-tremorine activity in anti-parkinsonian and related drugs. Br. J. Pharmacol. 18:1962;247-250.
4. Baez L.A. Arousal and consummatory behavior. Glik S.D, Goldfarb J. Behavioral Pharmacology. 1976;40-175 The C.V. Mosby Company, St. Louis.
5. Burns R.S., Le Witt P.A., Ebert M.H., Pakkenberg H., Kopin I.J. The clinical syndrome of striatal dopamine deficiency, parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP). New Engl. J. M. 312:1985;1418-1421.
6. Carlsson A., Lindquist M., Magnusson T. 3,4-Dihydroxyphenylaine and 5-hydroxytryptophan as reserpine antagonists. Nature. 180:1957;1200.
7. Cooper D.R., Marrel C., Van de Materbend H., Testa B., Jenner P., Marsden C.D. L-Dopa esters as potential prodrugs, behavioural activity in experimental models of Parkinson's disease. J. Pharmacol. 39:1987;627-635.
8. Grabarevic Z., Tisljar M., Artukovic B., Bratulic M., Dzaja P., Seiwerth S., Sikiric P., Peric J., Geres D., Kos J. The influence of BPC 157 on nitric-oxyde agonists and antagonist induced lesions in broiler chicks. J. Physiol. 91:1997;139-150.
9. Haggendal J., Lindquist M. Brain monoamine levels and behaviour during long-term administration of reserpine. Int. J. Neuropharmacol. 3:1964;59-64.
10. Haglund L., Kohler C., Haaparanta T., Goldstein M., Gustafsson J.A. Presence of NADPH-cytochrome P450 reductase in central catecholaminergic neurones. Nature. 307:1984;259-262.
11. Heikkila R.E., Sonsalla P.K. The use of MPTP-treated mouse as an animal model of parkinsonism. Can. J. Neurol. 14:1987;436-440.
12. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311:1984;467-469.
13. Hernandez D.E. The role of brain peptides in the pathogenesis of experimental stress gastric ulcers. Ann. N. Y. Acad. Sci. 597:1990;28-35.
14. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-964.
15. Jelovac N., Sikiric P., Rucman R., Petek M., Perovic D., Konjevoda P., Marovic A., Seiwerth S., Grabarevic Z., Sumajstorcic J., Dodig G. A novel pentadecapeptide BPC 157 blocks the stereotypy produced acutely by amphetamine and the developement of haloperidol-induced supersensitivity to amphetamine. Biol. Psych. 43:1998;511-519.
16. Johannessen J.N., Adams J.D., Schuller H.M., Bacon J.P., Markey S.P. 1-Methyl-4-phenylpyridine induces oxidative strsss in the rodent. Life Sci. 38:1986;743-749.
17. Kaakkola S., Teräväinen H. Animal models of Parkinsonism. Pharmacol. Toxicol. 67:1990;95-100.
18. Knoll J., Dalco J., Yen T.T. Striatal dopamine, sexual activity and lifespan. Longevity study of rats treated with (-)deprenyl. Life Sci. 45:1989;525-531.
19. Langston J.W., Irwine I. Pyrodine toxins. Calne D.B. Handbook of Experimental Pharmacology, vol. 88. 1989;203-226 Springer Verlag, Berlin, Heidelberg.
20. Langston J.W., Ballard P., Tetrud J.W., Irwing I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
21. Mardsen C.D. Parkinson's disease. Lancet. 1:1990;948-952.
22. Paré W., Kluczynski J.M. The effect of new gastric juice peptide BPC on classic stress trial in stress procedure. Exp. Clin. Gastroenterol. 4:1994;234-236.
23. Parmar N.S., Tariq M., Ageel A.M. Effect of bromocriptine a dopamine receptor agonist on experimentaly induced gastric ulcers in albino rats. Life Sci. 35:1984;2035-2039.
24. Sandor Z., Vincze A., Szabo S. The protective effect of a recently isolated gastric peptide in acute and chronic gastroduodenal injury. FASEB J. 10:1996;171.
25. Segal D.S., Sullivan J.L., Kuczenski R.T., Mandell A.J. Effects of long-term reserpine treatment on brain tyrosine hydroxylase and behavioral actifvity. Science. 173:1971;847-849.
26. Seiwerth S., Sikiric P., Grabarevic Z., Zoricic I., Hanzevacki M., Ljubanovic D., Coric V., Konjevoda P., Petek M., Rucman R., Turkovic B., Perovic D., Mikus D., Jadrijevic S., Medvidovic M., Tadic T., Romac B., Kos J., Peric J., Kolega Z. BPC 157 effect on healing. J. Physiol. (Paris). 91:1997;173-178.
27. Sershen A., Reith M.E.A., Hashim A., Lajtka A. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid. Neuropharmacology. 24:1985;1257-1259.
28. Sikiric P., Geber J., Ivbanovic D., Suchanek E., Gjuris V., Tucan-Foretic M., Mise S., Cvitanovic B., Rotkvic I. Dopamine antagonists induce gastric lesions in rats. Eur. J. Pharmacol. 131:1986;105-109.
29. Sikiric P., Rotkvic I., Mise S., Krizanac S., Gjuris V., Jukic J., Suchanek E., Petek M., Udovicic I., Kalogjera L., Geber J., Tucan-Foretic M., Duvnjak M., Philipp M., Balen I., Anic T. The influence of dopamine agonists and antagonists on indomethacin lesions in stomach and small intestine in rats. Eur. J. Pharmacol. 158:1988;61-67.
30. Sikiric P., Banic M., Brkic T., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Anic B., Rotkvic I., Duvnjak M., Veljaca M., Simicevic V. Effect of a novel pentadecapeptide BPC 157 and methylprednisolone in a murine model of inflammatory bowel disease. Gastroenterology. 104:1993;782.
31. Sikiric P., Gyires K., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Rotkvic I., Turkovic B., Udovicic I., Jagic V., Mildner B., Duvnjak M., Danilovic Z. The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology. 2:1993;121-127.
32. Sikiric P., Petek M., Rucman R., Seiwerth S., Grabarevic Z., Rotkvic I., Turkovic B., Jagic V., Mildner B., Duvnjak M., Lang N. A new gastric juice peptide BPC - an overview of stomach/stress/organoprotection hypothesis and BPC beneficial effects. J. Physiol. (Paris). 87:1993;313-327.
33. 4 application. A comparative study with dopamine agonists and somatostatin. Life Sci. 53:1993;PL291-PL296.
34. 2 receptor antagonists, dopamine promotors and gut peptides. Life Sci. 54:1994;PL63-PL68.
35. Sikiric P., Rotkvic I., Mise S., Seiwerth S., Grabarevic Z., Petek M., Rucman R., Zjacic-Rotkvic V., Duvnjak M., Jagic V., Suchanek E., Marovic A., Banic M., Brkic T., Hanzevacki M., Separovic J., Djacic S., Simicevic V. Dopamine agents efficacy in peptic ulcer healing and relapse prevention - a further indication for importance of stomach dopamine in the stress organoprotection concept. Szabo S, Taché Y, Glavin G. Neuroendocrinology of Gastrointestinal Ulceration, Hans Selye Symposia on Neuroendocrinology and Stress, vol. 2. 1995;221-230 Plenum Publishing Corporation, New York.
36. Sikiric P., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Jagic V., Turkovic B., Rotkvic I., Mise S., Zoricic I., Gjurasin M., Konjevoda P., Separovic J., Ljubanovic D., Artukovic B., Bratulic M., Tisljar M., Jurina L.J., Buljat G., Miklic P., Marovic A. The beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin and capsaicin neurotoxicity. Dig. Dis. Sci. 41:1996;1604-1614.
37. Sikiric P., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Jagic V., Turkovic B., Rotkvic I., Mise S., Zoricic I., Jurina J., Konjevoda P., Hanzevacki M., Ljubanovic D., Separovic J., Gjurasin M., Bratulic M., Artukovic B., Jelovac N., Buljat G. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig. Dis. Sci. 41:1996;1518-1526.
38. Sikiric P., Mazul B., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Jagic V., Turkovic B., Rotkvic I., Mise S., Zoricic I., Jurina L., Konjevoda P., Hanzevacki M., Gjurasin M., Separovic J., Ljubanovic D., Artukovic M., Bratulic M., Tisljar M., Miklic P., Sumajstorcic J. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig. Dis. Sci. 42:1997;661-671.
39. Sikiric P., Mikus D., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Jagic V., Turkovic B., Rotkvic I., Mise S., Zoricic I., Peric J., Konjevoda P., Perovic D., Jurina L., Hanzevacki M., Separovic J., Gjurasin M., Jadrijevic S., Jelovac N., Miklic P., Buljat G., Marovic A. Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine and atropine effect in cysteamine lesions in totally gastrectomized rats. A model study for cytoprotective studies. Dig. Dis. Sci. 42:1997;1029-1037.
40. G-nitro-L-arginine methylester and L-arginine effect on stomach mucosal integrity and blood pressure. Eur. J. Pharmacol. 332:1997;23-32.
41. Sikiric P., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Jagic V., Turkovic B., Rotkvic I., Mise S., Zoricic I., Perovic D., Simicevic V., Hanzevacki M., Ljubanovic D., Artukovic M., Bratulic M., Tisljar M., Rekic B., Gjurasin M., Miklic P., Buljat G. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agents-induced gastrointestinal lesions and adjuvant arthritis in rats. J. Physiol. (Paris). 91:1997;113-122.
42. Sofia R.D., Kubena R.K., Barry H. Ianctivity of delta9-tetrahydrocarnabinol in antidepressant screening tests. Psychopharmacologia. 31:1973;121-130.
43. Strabg R.R. The occurrence of peptic ulceration in patients with parkinsonism. Acta Neurol. Scand. 42:1965;124-127.
44. Szabo S. Dopamine disorder in duodenal ulceration. Lancet. 2:1979;880-882.
45. Szabo S., Neumeyer J.L. Dopamine agonists and antagonists in duodenal ulcer disease. Kaiser C, Kebabian W. ACS Symposium Series. 1983;175-196 American Chemical Society Publications, Washington.
46. Szabo S., Brown A., Pihan G., Dali A., Neumeyer J.L. Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine). Proc. Soc. Exp. Biol. M. 180:1985;567-571.
47. Trendelenburg U.G. Time course of changes in sensitivity after denervation of the nictating membrane of the spinal cat. J. Pharmacol. Exp. Ther. 142:1963;335-342.
48. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxsidopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 367 (Suppl.):1971;69-93.
49. Ungerstedt U., Avemo A., Avemo E., Ljungberg T., Ranje C. Animal models of Parkinsonism. Adv. Neurol. 3:1973;257-271.
50. Veljaca M., Lech C.A., Pllana R., Sanchez B., Chan K., Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J. Pharmacol. Exp. Ther. 272:1994;417-422.
51. Veljaca M., Pllana R., Lesch C.A., Sanchez B., Chan K., Guglietta A. Protective effect of BPC 157 on a rat model of colitis. Gastroenterology. 106:1994;789.
52. Veljaca M., Lesch C.A., Sanchez B., Low J., Guglietta A. Protection of BPC-15 on TNBS-induced colitis in rats: possible mechanisms of action. Gastroenterology. 108:1995;936.
53. Wagner G.C., Jarvis M.F., Carelli R.M. Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmacology. 24:1985;1261-1262.
54. Weihmuller F.B., Hadjiconstantinou M., Bruno J.P. Dissociation between biochemical and behavioral recovery in MPTP-treated mice. Pharm. Biochem. Behav. 34:1989;113-117.
55. Wiener H.L., Hashim A., Lajtha A., Sershen H. (-)-2-Oxo-4-thiazolidine carboxylic acid attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity. Res. Commun. Subst. Abuse. 9:1988;53-60.